AbbVie Submits Biologics License Application (BLA) for Etentamig to U.S. FDA for Adults Living With Relapsed/Refractory Multiple Myeloma

Etentamig is described as a second-generation BCMA-directed bispecific antibody T-cell engager, with a clinical profile and dosing schedule that may support use across multiple care settings, including community-based care. The article fragment says the drug achieved an outcome in the Phase 3 CERVINO study but omits what that outcome was.